Safety profile of pertuzumab with trastuzumab and docetaxel in patients from asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA

Oncologist

Volumn 19, Issue 7, 2014, Pages 693-701

  Swain, Sandra M ^a   Im, Young Hyuck ^b   Im, Seock Ah ^c   Chan, Valorie ^d   Miles, David ^e   Knott, Adam ^f   Clark, Emma ^f   Ross, Graham ^f   Baselgag, José ^g  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Veterans Memorial Medical Center Cancer Research Center   (Philippines)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Asia; Febrile neutropenia; HER2 positive metastatic breast cancer; Pertuzumab; Trastuzumab

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHARMACOLOGICAL BIOMARKER; TAXOID;

ADULT; AGED; ALOPECIA; ARTICLE; ASIA; BREAST METASTASIS; CANCER INCIDENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BREAST NEOPLASMS; CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 84903638071     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0033     Document Type: Article

References (47)

1. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43.
2. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009;14:320-368.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl JMed 2005;353: 1659-1672.
4. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl JMed 2006;355:2733-2743.
5. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
6. Slamon D, EiermannW, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011;365:1273-1283.
7. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
8. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
9. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
10. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-471.
11. Baselga J, Cortés J, Im S-A et al. Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. Poster presented at: 48th Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, IL.
12. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187-3205.
13. AnderssonM, Lidbrink E, BjerreKet al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as firstline therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol 2011;29:264-271.
14. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196.
15. Hirth J, Watkins PB, StrawdermanMet al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6: 1255-1258.
16. Yamamoto N, Tamura T, Kamiya Y et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18: 2301-2308.
17. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79:570-580.
18. Shou M, MartinetM, Korzekwa KRet al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution inhumanliver. Pharmacogenetics 1998;8:391-401.
19. Guengerich FP. Polymorphism of cytochrome P-450 in humans. Trends Pharmacol Sci 1989;10: 107-109.
20. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 59 promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-294.
21. Lamba JK, Lin YS, Thummel K et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-132.
22. Lamba JK, Lin YS, Schuetz EG et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-1294.
23. Maekawa K, Harakawa N, Yoshimura T et al. CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 2010;38:2100-2104.
24. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;11:77-98.
25. Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on bodysurface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-1069.
26. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
27. Lin Y, Anderson GD, Kantor E et al. Differences in the urinary excretion of 6-beta-hydroxycortisol/ cortisol between Asian and Caucasian women. J Clin Pharmacol 1999;39:578-582.
28. Ahsan CH, Renwick AG, Waller DG et al. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993;54:329-338.
29. Ma B, Yeo W, Hui P et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer-A retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62:185-189.
30. Han HS, Reis IM, Zhao W et al. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 2011;47:2537-2545.
31. Cortés J, Swain SM, Kudaba I et al. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs 2013;24:1084-1092.
32. Royer I, Monsarrat B, Sonnier M et al. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56:58-65.
33. Keizer RJ, Huitema AD, Schellens JH et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49: 493-507.
34. ScheuerW, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-9336.
35. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
36. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421: 756-760.
37. Sawyer M, Ratain MJ. Body surface area as adeterminant ofpharmacokineticsanddrug dosing. Invest New Drugs 2001;19:171-177.
38. Rivory LP, Slaviero K, Seale JP et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000;6:3480-3485.
39. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-3690.
40. Puisset F, Chatelut E, Dalenc F et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004;54:265-272.
41. Rivory LP, Slaviero KA, Hoskins JM et al. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 2001;40:151-158.
42. Farrell GC, Zaluzny L. Accuracy and clinical utility of simplified tests of antipyrine metabolism. Br J Clin Pharmacol 1984;18:559-565.
43. Watkins PB, Turgeon DK, Saenger P et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-273.
44. Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
45. Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
46. Calvert AH. Dose optimisation of carboplatin in adults. Anticancer Res 1994;14:2273-2278.
47. Duff JM, Leather H, Walden EO et al. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-705.